SGEN Add to watchlist
$228.74 0.16 (-0.07%)
After Hours: $228.74 +0.00 (+0.00%)
Last updated: Aug 11, 2026 21:10
52-Week Range
$228.74
$182.99 $228.74 $274.49

Fundamentals Overview

Seagen Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

PEG 3.6 P/B 8.46 P/S 12.09

Risk (Beta)

0.32 — lower vol

Earnings & growth

EPS $-3.30 Rev +7.4% Profit -2% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 40% confidence Risk: Lower Volatility — Beta 0.32. Diversify and only invest what you can afford to lose.

Pressures (Sell):

PEG 3.6

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$43.15B
P/E (TTM)
N/A
EPS (TTM)
$-3.30
Dividend Yield
N/A
52-Week Range
$182.99 - $274.49
Volume vs Avg
N/A
Beta
0.32

About

Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling...
Sector: Healthcare
Headquarters: US
Employees: 3,256
IPO Date: Mar 2001
Beta: 0.32 (Less volatile than market)

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) 3.6
P/B (TTM) 8.46
P/S (TTM) 12.09
Liquidity & enterprise
Current Ratio (TTM) 2.12
Quick Ratio (TTM) 1.6
Cash Ratio (TTM) 0.39
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -31.1%
Gross margin (TTM) 79.1%
Operating margin (TTM) -31.24%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for SGEN.

Price target data is not available for this symbol from the current data source.

Stock Grades (Institutions)

No stock grades available for this symbol.

No price targets, ratings snapshot, or grades available for this symbol.